TABLE 3.

Comparison of predose (and 24 h for QD) values for ZDV and 3TC metabolites on QD and BID regimens collapsed over order of administration

VariableDosing regimenn<LLOQ (n)aMedianb (95% CI)CVc (%)P (dose effect)d
ZDVQD27523.5 (12.1-40.2)191.10.560
BID26323.5 (8.7-40.8)251.8
ZDV-MPQD27276.2 (57.7-131.5)183.00.666
BID26275.3 (32.4-172.6)153.8
ZDV-DPQD27411.5 (9.2-19.1)108.70.594
BID26112.2 (7.7-22.9)90.2
ZDV-TPQD2739.3 (6.4-12.9)74.20.056
BID26315.4 (7.7-23.6)96.5
3TCQD262302 (204-441)195.80.142
BID271437 (284-632)113.6
3TP-MPQD262282 (205-390)92.80.107
BID272396 (238-529)129.8
3TC-DPQD2611,934 (1,359-2,476)87.50.170
BID2712,393 (1,194-2,931)92.5
3TC-TPQD2511,115 (724-2,445)90.10.090
BID2712,163 (671-3,790)97.3
24 hQD
ZDV27223.6 (11.4-38.4)134.3
ZDV-MP27060.5 (38.8-84.4)107.3
ZDV-DP27211.1 (7.9-19.9)79.5
ZDV-TP2749.8 (4.9-13.2)84.2
3TC273262 (208-452)80.5
3TC-MP271353 (225-401)62.8
3TC-DP2701,684 (932-2,683)63.2
3TC-TP2711,315 (988-2,463)88.0
  • a That is, the number of measurements where one-half the lower limit of quantification (LLOQ) was imputed.

  • b Median and 95% CI reported in fmol/106 cells for ZDV and in pmol/106 cells for 3TC.

  • c CV, coefficient of variation.

  • d Significance value as determined by the Wilcoxon rank-sum test for differences in median values on the QD versus the BID regimen.